How much will Pimitespib cost in Japan in 2025?

Pimitespib is a new oral HSP90 inhibitor developed by JapanTaiho Pharmaceutical. It is currently only approved for marketing in the Japanese market. It is indicated for patients with gastrointestinal stromal tumors (GIST) whose disease has progressed despite previous standard treatments. Since the drug has not yet been approved for marketing in mainland China, domestic patients who need to use it can only obtain the original version of the drug through legal overseas drug purchase channels or international medical institutions. Pimetibi is clinically positioned as a treatment option after the failure of other targeted drugs (such as imatinib, regorafenib, etc.). It has certain clinical supplementary value, especially in the face of multi-drug resistance problems, showing potential.

As for the price of pimetibib in Japan, the version currently on the market is the original drugJeselhy, with a specification of 40 mg × 40 tablets/box. According to public price references around 2024, each box sells for about 19,000 yuan. The specific value will fluctuate with changes in the Japanese yen exchange rate and supply channels. Since there are no generic drugs yet, the price is relatively stable and at a high level, which puts a heavy financial burden on patients who need to take medicine for a long time, especially if they purchase the medicine at their own expense.

Currently, there are no generic drugs of Pimitibi or biosimilars applied for production by other companies on the market, which means that the price of the drug will remain at the high level of the exclusive pricing of the original manufacturer in the next few years. In addition, although Japan has included pimetibib in its medical insurance catalog, and local patients can partially reduce their drug burden with the support of medical insurance, this preferential policy does not apply to non-citizens. Therefore, Chinese patients who obtain Jeselhy through overseas medical services or third-party drug purchasing platforms still need to bear the full cost.

Reference materials:https://en.wikipedia.org/wiki/Pimitespi